Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TBA-354 in Healthy Adult Subjects
NCT02606214Phase 1Terminated
- Sponsor
- TB Alliance
- Start
- Nov 2015
- Primary completion
- Dec 2015
01
Overview
Phase 1, randomised, double-blind trial of TBA-354 in Tuberculosis (TB) (7 arms), sponsored by TB Alliance. Primary endpoints: Treatment Emergent Adverse Events and Change-from-baseline QTcF intervals. Started Nov 2015; status: terminated.
02
Drugs
TBA-354
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT02606214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02606214.